Furthermore, Singh and colleagues reported that the exogenous administration of CGRP suppressed macrophage infiltration and inflammatory cytokine secretion, which attenuated Alzheimer's disease (AD), suggesting that CGRP is a potential candidate target for the treatment of AD (19). The gene discussed is CALCA; the disease is early-onset autosomal dominant Alzheimer disease.